

**CRITICAL LIMB ISCHEMIA VOLUME I
TABLE OF CONTENTS**

CONCLUSION	7
U.S. CRITICAL LIMB ISCHEMIA PREVALENCE.....	7
MARKET IMPLICATIONS—ENDOVASCULAR	7
MARKET IMPLICATIONS—PHARMACEUTICAL.....	7
MARKET IMPLICATIONS—MECHANICAL THROMBECTOMY	7
MARKET FOR PATIENTS WHO CANNOT BE REVASCULARIZED.....	8
DIAGNOSTIC MARKET	8
NEW MARKET FOR ADJUNCT THERAPY IN REVASCULARIZED PATIENTS.....	8
OPTIMUM METHODS TO ESTIMATE CLI	8
INTRODUCTION	9
PURPOSE.....	9
METHODS	10
PERIPHERAL ARTERIAL DISEASE (PAD)	11
INTERMITTENT CLAUDICATION	11
AN UNCOMMON SYMPTOM	11
LIMB ISCHEMIA	11
ACUTE LIMB ISCHEMIA (ALI)—LEG ATTACK	12
<i>Location</i>	12
<i>Occlusion Classification System</i>	12
CRITICAL LIMB ISCHEMIA (CLI)	12
<i>Symptoms</i>	13
<i>Risk Factors</i>	13
<i>A Bilateral Disease</i>	13
<i>Multilevel Disease</i>	13
CLI—CLINICAL CLASSIFICATION	14
FONTAINE DISEASE CLASSIFICATION SYSTEM	14
RUTHERFORD CLASSIFICATION SYSTEM.....	15
CHRONIC ISCHEMIA	15
VESSEL ALTERATIONS, TISSUE DAMAGE AND SYSTEMIC EFFECTS	15
ENDOTHELIAL DYSFUNCTION.....	15
COLLATERAL VESSEL GROWTH SUPPRESSED.....	16
<i>Factors Inhibiting Growth</i>	16
INADEQUATE BLOOD FLOW AND PRESSURE DAMAGES MICROCIRCULATION.....	16
MALFUNCTION RESULTS IN STATE OF VASODILATION AND UNREGULATED BLOOD FLOW.....	16
<i>Excessive Blood Floods Capillaries</i>	16
EDEMA	17
SHORT-TERM CONSEQUENCES—DEATH AND LIMB LOSS	17
SIX MONTHS—20% MORTALITY AND 40% AMPUTATION	17
PATIENTS UNSUITABLE FOR REVASCULARIZATION	18
HIGH ONE-YEAR AMPUTATION RATE	18
ABI INVERSELY ASSOCIATED WITH AMPUTATION	18
OUTCOMES IN REVASCULARIZED PATIENTS	19
30-DAY MORTALITY AND AMPUTATION	19
<i>The Swedish Vascular Registry (Swedvasc)</i>	19

<i>Bypass versus Angioplasty in Severe Ischemia of the Leg (BASIL) Trial</i>	19
<i>Project or Ex-Vivo Vein Graft Engineering via Transfection Study III (PREVENT III)</i>	20
THREE-MONTH OUTCOMES	21
ONE-YEAR OUTCOME	21
END-STAGE DISEASE—30% FIVE YEAR SURVIVAL	21
FIVE-YEAR MORTALITY EXCEEDS MOST OTHER DEADLY DISEASES	21
DISEASE SEVERITY REDUCES SURVIVAL.....	22
FOUR-YEAR EVENT-FREE SURVIVAL DECLINES WITH DISEASE SEVERITY	22
LONG-TERM MORTALITY INCREASES WITH DISEASE SEVERITY.....	23
CAUSE OF DEATH.....	24
SERIOUS COMORBIDITIES	25
DIABETES.....	25
DIABETES DEFINED	25
<i>A Note on Diabetes Terminology</i>	26
PREDIABETES DEFINED	26
RISK FACTORS.....	26
MORTALITY.....	26
DIABETES AND PREDIABETES—AN EPIDEMIC	26
DIABETES AND PREDIABETES—35% OF THE U.S. ADULT POPULATION	26
DIABETES AND RACE/ETHNICITY	27
DIABETES PREVALENCE INCREASES WITH AGE	27
DIABETES AND PAD	28
PAD PREVALENT IN DIABETICS	28
DIABETIC ABNORMALITIES PROMOTE ATHEROSCLEROSIS AND THROMBOSIS.....	29
<i>Structural and Functional Vessel Abnormalities</i>	29
<i>Endothelial Dysfunction</i>	29
<i>Hypercoagulable State</i>	29
GREATER RISK OF DEVELOPING PAD	29
FACTORS THAT INCREASE RISK OF PAD IN DIABETICS	29
EXCESS CARDIOVASCULAR MORBIDITY AND MORTALITY	30
DISEASE LOCATED BELOW THE KNEE	30
THE NEUROISCHEMIC FOOT	30
NEUROPATHY IS COMMON	30
CAUSED BY MICROCIRCULATORY DYSFUNCTION AND METABOLIC ABNORMALITIES	30
A BIOLOGICALLY COMPROMISED FOOT VULNERABLE TO ISCHEMIA	31
PROPENSITY TO DEVELOP ULCERS, INFECTION AND GANGRENE.....	31
<i>Eurodiale—High Prevalence of PAD in Patients with Foot Ulcers</i>	31
FOOT ULCERS PRECEDE AMPUTATIONS	32
DIABETES AND CRITICAL LIMB ISCHEMIA	32
HIGHER RISK OF CLI AND MORE SEVERE DISEASE	32
DIABETIC PATIENTS PRESENT WITH ADVANCED ISCHEMIA	33
CLI DEVELOPS SUDDENLY.....	34
DIABETES INCREASES THE RISK OF AMPUTATION	34
<i>Risk of Amputation Related to Severity of Diabetes</i>	34
HIGHER MORTALITY	34
ADDITIONAL RISK FACTORS INCREASE SEVERITY	35
<i>Diabetes and Smoking—A Deadly Combination</i>	35

CHRONIC KIDNEY DISEASE (CKD)	35
DEFINITIONS	35
DRAMATIC INCREASE IN U.S. ESRD PATIENTS	35
ESRD ASSOCIATED WITH HIGH INCIDENCE OF CARDIOVASCULAR MORBIDITY AND MORTALITY	36
<i>Morbidity and Mortality Increase with Severity of CKD</i>	37
CALCIFICATION	37
<i>Present in 40% to 70% of ESRD Patients</i>	37
<i>Associated with Diabetes</i>	37
PAD AND CKD	37
PAD COMMON IN DIALYSIS PATIENTS	37
DIALYSIS OUTCOMES AND PRACTICE PATTERNS STUDY (DOPPS)	38
CKD INCREASES THE RISK FOR DEVELOPING PAD.....	39
<i>PAD Incidence and Prevalence Higher in More Severe Disease</i>	39
ABI PREDICTS MORTALITY IN ESRD.....	39
KIDNEY DISEASE, DIABETES AND PAD—A LIFE AND LIMB THREATENING COMBINATION	39
HIGH PREVALENCE OF PAD IN PATIENTS WITH BOTH CHRONIC KIDNEY DISEASE AND DIABETES.....	39
PATIENTS WITH KIDNEY FAILURE CAUSED BY DIABETES—PAD PRESENT IN 36%	40
PAD INCIDENCE HIGHEST IN PATIENTS WITH DIABETES AND KIDNEY DISEASE	40
SIGNIFICANTLY HIGHER RISK OF AMPUTATION	41
CRITICAL LIMB ISCHEMIA AND CHRONIC KIDNEY DISEASE	41
CRITICAL LIMB ISCHEMIA COMMON IN ESRD PATIENTS	41
CLI SEVERITY RELATED TO SEVERITY OF KIDNEY DYSFUNCTION.....	41
MORTALITY	42
<i>Critical Limb Ischemia Predicts All-Cause Mortality</i>	42
<i>Renal Dysfunction Predicts Mortality in Critical Limb Ischemia</i>	42
AMPUTATION MORE LIKELY IN DIALYSIS PATIENTS	44
<i>Concurrent with Revascularization</i>	44
<i>Poor Amputation-Free Survival</i>	44
DISEASE LOCATED BELOW THE KNEE	45
CLI—A PRIMARY CAUSE OF DEATH IN ESRD?.....	45
ESTIMATING THE PREVALENCE OF CLI	47
METHODS	47
INCIDENCE AND PREVALENCE DEFINED	47
SUMMARY OF INCIDENCE ESTIMATES	48
INCIDENCE—OVERVIEW OF METHODS	48
PROGRESSION FROM IC	49
2006 INCIDENCE ESTIMATE	49
LIMITATIONS	49
NUMBER OF HOSPITALIZATIONS OR REVASCULARIZATION PROCEDURES	49
LIMITATIONS	49
NUMBER OF AMPUTATIONS	50
2006 INCIDENCE ESTIMATE	50
LIMITATIONS	50
COMBINATION METHODS—ITALIAN STUDY	50
2006 INCIDENCE ESTIMATE	50

SURVEY OF VASCULAR SURGEONS IN GREAT BRITAIN AND IRELAND.....	50
CLI INCIDENCE ESTIMATE.....	51
STUDY DESCRIPTION.....	51
UNDERESTIMATES NUMBER WITH CLI.....	51
OXVASC—POPULATION BASED INCIDENCE BY AGE AND SEX	52
DESCRIPTION.....	52
INCIDENCE BY AGE AND SEX.....	52
2006 INCIDENCE ESTIMATE	53
LIMITATIONS	53
PREVALENCE ESTIMATED FROM INCIDENCE.....	53
SUMMARY OF CLI PREVALENCE ESTIMATES.....	54
DISEASE PROGRESSION IN IC PATIENTS	55
2006 PREVALENCE ESTIMATE	55
LIMITATIONS ASSOCIATED WITH DISEASE PROGRESSION FROM IC	55
<i>Based on the Minority of PAD Patients</i>	<i>55</i>
<i>Excludes Non-IC Patients</i>	<i>55</i>
SHORTCOMINGS IN OLDER STUDIES THAT MEASURED PROGRESSION.....	56
AS MANY AS HALF OF CLI PATIENTS DEVELOP CLI WITHOUT PRIOR SYMPTOMS	56
IC MAY PROGRESS TO CLI AT HIGHER RATES	56
PREVALENCE BASED ON POPULATION SURVEYS	57
HUNT STUDY	57
DESCRIPTION.....	57
RESULTS BY AGE AND SEX.....	57
2006 PREVALENCE ESTIMATE	58
LIMITATIONS	58
2006 PREVALENCE ADJUSTED FOR POPULATION 70 YEARS AND OLDER.....	58
<i>Based on 60%-80% CLI Occurring in Population Age 70 and Older</i>	<i>58</i>
<i>Based on 5%-10% of Population Age 70-79 with CLI.....</i>	<i>58</i>
NEW SOUTH WALES RURAL COMMUNITY STUDY	59
RESULTS.....	59
2006 PREVALENCE ESTIMATE	60
CLI PREVALENCE ESTIMATED FROM PAD POPULATION.....	60
PAD PROJECTIONS	60
METHOD —PAD POPULATION BY DISEASE SEVERITY	61
2006 CLI PREVALENCE	61
CLI PREVALENCE ESTIMATED FROM HIGH RISK GROUP—DIABETICS.....	61
A NOTE ON PAD DIAGNOSTIC METHOD	61
<i>Limitations of ABI < 0.90</i>	<i>62</i>
<i>Abnormally High ABI May Also Indicate Disease.....</i>	<i>62</i>
PAD PREVALENCE IN DIABETES.....	62
CARDIOVASCULAR HEALTH STUDY	64
THE HOORN STUDY	64
SEATTLE STUDY OF DIABETIC AND NONDIABETIC VOLUNTEERS AGE 12-90	65
NEWLY DIAGNOSED DIABETICS IN ITALY	66
KRISTIANSTAD POPULATION-BASED STUDY	66
FREMANTLE DIABETES STUDY	66

DIABETICS IN A MICHIGAN HMO	67
SMALL PILOT STUDY IN ENGLISH HOSPITAL CLINIC	67
DIABETICS IN HELSINKI.....	67
THE ‘MEN BORN IN 1914’ STUDY	67
POPULATION IN EAST DORSET, ENGLAND	68
GERMAN EPIDEMIOLOGICAL TRIAL ON ANKLE BRACHIAL INDEX (GETABI)	68
NHANES II—PHYSICIANS EXAMINATION.....	69
NHANES 1999-2000.....	69
NHANES 1999-2002—ELDERLY DIABETICS	69
CLI ESTIMATES BASED ON DIABETES METHOD	70
ESTIMATION METHODS AND ASSUMPTIONS	71
POPULATION AGE 65 AND OLDER	71
<i>Glucose Status by Sex</i>	71
<i>PAD Prevalence by Glucose Status</i>	72
<i>Critical Limb Ischemia by Glucose Category</i>	72
POPULATION AGE 45-64.....	72
<i>Glucose Status</i>	73
<i>PAD Prevalence by Glucose Status</i>	73
<i>Critical Limb Ischemia by Glucose Status</i>	73
PAD AND CLI ESTIMATES BASED ON INCREASING PREVALENCE OF DIABETES	74
CLI PROJECTIONS.....	75
CRITICAL LIMB ISCHEMIA—MARKET IMPLICATIONS	76
ENDOVASCULAR MARKET	76
METHODS AND ASSUMPTIONS—CURRENT MARKET.....	76
METHODS AND ASSUMPTIONS—POTENTIAL MARKET	77
<i>Actual CLI Treatment Pathway Often Differs from the Ideal</i>	79
IMPACT OF NEW ENDOVASCULAR TECHNOLOGIES.....	79
GREATER SHARE OF LIMBS TREATED.....	79
SIGNIFICANT INCREASE IN MARKET VALUE	79
STENTS.....	80
CURRENT STENT MARKET.....	80
POTENTIAL IMPACT OF NEW STENT TECHNOLOGY.....	81
PHARMACEUTICAL THERAPIES	82
RISK FACTOR MODIFICATION	82
ANTIHYPERTENSIVES	82
ANTILIPIDS	83
ANTIPLATELETS	83
NO REVASCULARIZATION PATIENTS	84
DIAGNOSTIC MARKET	84
ADJUNCT THERAPY IN REVASCULARIZED PATIENTS.....	84
BYPASS PATIENTS	84
ENDOVASCULAR PATIENTS	84
THROMBOLYTICS.....	85
MECHANICAL THROMBECTOMY	85

APPENDIX A	86
COMPARISON OF PAD ESTIMATES WITH PREVIOUS ESTIMATES.....	86
REFERENCES	87
INDEX OF TABLES.....	102
INDEX OF FIGURES.....	105
GLOSSARY	107
DISCLOSURE STATEMENT	108
CONTACT INFORMATION	109